Your browser doesn't support javascript.
loading
Impact of Prior Antiplatelet Therapy on Outcomes After Endovascular Therapy for Acute Stroke: Endovascular Treatment in Ischemic Stroke Registry Results.
Couture, Marie; Finitsis, Stephanos; Marnat, Gaultier; Richard, Sébastien; Bourcier, Romain; Constant-Dits-Beaufils, Pacôme; Dargazanli, Cyril; Arquizan, Caroline; Mazighi, Mikaël; Blanc, Raphaël; Eugène, François; Vannier, Stéphane; Spelle, Laurent; Denier, Christian; Touzé, Emmanuel; Barbier, Charlotte; Saleme, Suzana; Macian, Francisco; Rosso, Charlotte; Clarençon, Frédéric; Naggara, Olivier; Turc, Guillaume; Ozkul-Wermester, Ozlem; Papagiannaki, Chrysanthi; Viguier, Alain; Cognard, Christophe; Lebras, Anthony; Evain, Sarah; Wolff, Valérie; Pop, Raoul; Timsit, Serge; Gentric, Jean-Christophe; Bourdain, Frédéric; Veunac, Louis; Lapergue, Bertrand; Consoli, Arturo; Gory, Benjamin; Sibon, Igor.
Afiliação
  • Couture M; Department of Neurology, Stroke Center (M.C., I.S.), University Hospital of Bordeaux, France.
  • Finitsis S; Interventional and Diagnostic Neuroradiology Department, AHEPA University Hospital, Thessaloniki, Greece (S.F.).
  • Marnat G; Department of Diagnostic and Interventional Neuroradiology (G.M.), University Hospital of Bordeaux, France.
  • Richard S; Stroke Unit, Department of Neurology, CHRU-Nancy (S.R.), Université de Lorraine, France.
  • Bourcier R; INSERM U1116, CHRU-Nancy, France (S.R.).
  • Constant-Dits-Beaufils P; Departments of Neuroradiology (R.B.), University Hospital of Nantes, France.
  • Dargazanli C; Neurology (P.C.-d.-B.), University Hospital of Nantes, France.
  • Arquizan C; Department of Interventional Neuroradiology, CHRU Gui de Chauliac, Montpellier, France (C.D.).
  • Mazighi M; Department of Neurology, CHRU Gui de Chauliac, Montpellier, France (C.A.).
  • Blanc R; Department of Interventional Neuroradiology, Rothschild Foundation, Paris, France (M.M., R.B.).
  • Eugène F; Department of Interventional Neuroradiology, Rothschild Foundation, Paris, France (M.M., R.B.).
  • Vannier S; Department of Neuroradiology, University Hospital of Rennes, France (F.E.).
  • Spelle L; Stroke Unit, Department of Neurology, University Hospital of Rennes, France (S.V.).
  • Denier C; Neuroradiolology (L.S.), CHU Kremlin Bicêtre, Paris, France.
  • Touzé E; Departments of Neurology (C.D.), CHU Kremlin Bicêtre, Paris, France.
  • Barbier C; Departments of Neurology (E.T.), CHU Caen, France.
  • Saleme S; Neuroradiology (C.B.), CHU Caen, France.
  • Macian F; Diagnostic and Interventional Neuroradiology (S.S), University Hospital of Limoges, France.
  • Rosso C; Departments of Neurology (F.M.), University Hospital of Limoges, France.
  • Clarençon F; Departments of Neurology (C.R.), CHU Pitié-Salpétrière, Paris, France.
  • Naggara O; Neuroradiolology (F.C.), CHU Pitié-Salpétrière, Paris, France.
  • Turc G; Neuroradiolology (O.N.), Hôpital Saint Anne, Paris, France.
  • Ozkul-Wermester O; Departments of Neurology (G.T.), Hôpital Saint Anne, Paris, France.
  • Papagiannaki C; Departments of Neurology (O.O.-W.), CHU Rouen, France.
  • Viguier A; Neuroradiolology (C.P.), CHU Rouen, France.
  • Cognard C; Departments of Neurology (A.V.), CHU Toulouse, France.
  • Lebras A; Neuroradiolology (C.C.), CHU Toulouse, France.
  • Evain S; Departments of Neurology (A.L.), CH Bretagne Atlantique, Vannes, France.
  • Wolff V; Neuroradiolology (S.E.), CH Bretagne Atlantique, Vannes, France.
  • Pop R; Departments of Neurology (V.W.), CHU Strasbourg, France.
  • Timsit S; Neuroradiolology (R.P.), CHU Strasbourg, France.
  • Gentric JC; Departments of Neurology (S.T.), CHU Brest, France.
  • Bourdain F; Neuroradiolology (J.-C.G.), CHU Brest, France.
  • Veunac L; Departments of Neurology (F.B.), CH Côte Basque, Bayonne, France.
  • Lapergue B; Neuroradiolology (L.V.), CH Côte Basque, Bayonne, France.
  • Consoli A; Department of Neurology, Foch Hospital (B.L.), Versailles Saint-Quentin en Yvelines University, Suresnes, France.
  • Gory B; Department of Diagnostic and Interventional Neuroradiology (A.C.), Versailles Saint-Quentin en Yvelines University, Suresnes, France.
  • Sibon I; Department of Diagnostic and Therapeutic Neuroradiology, CHRU-Nancy (B.G.), Université de Lorraine, France.
Stroke ; 52(12): 3864-3872, 2021 12.
Article em En | MEDLINE | ID: mdl-34538083
ABSTRACT
BACKGROUND AND

PURPOSE:

The influence of prior antiplatelet therapy (APT) uses on the outcomes of patients with acute ischemic stroke treated with endovascular therapy is unclear. We compared procedural and clinical outcomes of endovascular therapy in patients on APT or not before stroke onset.

METHODS:

We analyzed 2 groups from the ongoing prospective multicenter Endovascular Treatment in Ischemic Stroke registry in France patients on prior APT (APT+) and patients without prior APT (APT-) treated by endovascular therapy, with and without intravenous thrombolysis. Multilevel mixed-effects logistic models including center as random effect were used to compare angiographic (rates of reperfusion at the end of procedure, procedural complications) and clinical (favorable and excellent outcome, 90-day all-cause mortality, and hemorrhagic complications) outcomes according to APT subgroups. Comparisons were adjusted for prespecified confounders (age, admission National Institutes of Health Stroke Scale score, Alberta Stroke Program Early CT Score, intravenous thrombolysis, and time from onset to puncture), as well as for meaningful baseline between-group differences.

RESULTS:

A total of 2939 patients were analyzed, of whom 877 (29.8%) were on prior APT. Patients with prior APT were older, had more frequent vascular risk factors, cardioembolic stroke mechanism, and prestroke disability. Rates of complete reperfusion (37.9% in the APT- group versus 42.7 % in the APT+ group; aOR, 1.09 [95% CI, 0.88-1.34]; P=0.41) and periprocedural complication (16.9% versus 13.3%; aOR, 0.90 [95% CI, 0.7-1.2]; P=0.66) did not differ between the two groups. Symptomatic intracerebral hemorrhage (aOR, 0.93 [95% CI, 0.63-1.37]; P=0.73), 3 months favorable clinical outcome (modified Rankin Scale score of 0-2; aOR, 0.98 [95% CI, 0.77-1.25]; P=0.89), and mortality (aOR, 0.95 [95% CI, 0.72-1.26]; P=0.76) at 90 days did not differ between the groups.

CONCLUSIONS:

Prior APT does not influence angiographic and functional outcomes following endovascular therapy and should not be taken into account for acute revascularization strategies.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores da Agregação Plaquetária / Resultado do Tratamento / Procedimentos Endovasculares / AVC Isquêmico Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Stroke Ano de publicação: 2021 Tipo de documento: Article País de afiliação: França

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores da Agregação Plaquetária / Resultado do Tratamento / Procedimentos Endovasculares / AVC Isquêmico Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Stroke Ano de publicação: 2021 Tipo de documento: Article País de afiliação: França